
Bayer and Algeta have decided to avoid the usual M&A dance, opting instead to agree a business deal with little …
Bayer HealthCare is in the market to buy Norwegian oncology specialist Algeta. The German pharma group has made a bid …
Algeta has exercised its option to co-promote Alpharadin for the treatment of cancer patients with bone metastases in the United …

Bayer’s potential blockbuster prostate cancer drug Alpharadin has been granted a fast track review by the FDA, meaning it could …
Oslo-based oncology company Algeta has added Judith Hemberger and Kapil Dhingra to its board of directors. Judith Hemberger has more …
Brenntag and dsm-firmenich expand biopharma vitamin partnership
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership


